(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
China's Normal Ponders: A Visual Excursion - 2The Specialty of Cleaning up: Change Your Space and Brain
- 3Sean 'Diddy' Combs faces new sexual assault allegations, currently under investigation by Los Angeles Sheriff's Department
- 4An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Youngsters
- 56 U.S. States for Climbing
- The most effective method to Shake Hands Expertly: A Bit by bit Guide
- Traveling Alone: An Excursion of Self-Disclosure
- The Best Computer games for Multiplayer Fun
- A Texas GOP congressman is retiring. Trump just endorsed his identical twin to replace him.
- Iran denies launching ballistic missiles towards Kurdistan region of Iraq
- 5 Pizza Fixings That Characterize Your Character
- Fact Check: Some Bridge Photos Circulating Do NOT Show The Hongqi Bridge That Collapsed In Southwest China Nov. 11, 2025
- 5 Great Home Remodel Administrations With Green Arrangements In 2024
- Vote In favor of Your Favored Kind Of Cheddar
